{
  "directed": true,
  "graph": {
    "annotation_list": {},
    "annotation_pattern": {
      "Species": "^\\d+$"
    },
    "annotation_url": {
      "Anatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno",
      "Cell": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno",
      "CellLine": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno",
      "CellStructure": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno",
      "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno",
      "Disease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno",
      "Gender": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno",
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno",
      "MeSHDisease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno",
      "Subgraph": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno",
      "TextLocation": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"
    },
    "document_metadata": {
      "authors": "Esther Wollert",
      "contact": "charles.hoyt@scai.fraunhofer.de",
      "copyright": "Copyright Â© 2019 Fraunhofer Institute SCAI, All rights reserved.",
      "description": "",
      "licenses": "CC BY 4.0",
      "name": "PP2A and Alzheimer Disease",
      "version": "1.0.0"
    },
    "namespace_pattern": {
      "DBSNP": "rs[0-9]+",
      "PUBCHEM": "^\\d+$",
      "TAXONOMY": "^\\d+$",
      "UNIPROT": "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\\.\\d+)?$"
    },
    "namespace_url": {
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns",
      "CONSO": "https://raw.githubusercontent.com/pharmacome/conso/501ceccdc9a27d97edbdc48a89ebe8e1dd3626e9/export/conso-names.belns",
      "DRUGBANK": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/drugbank-names.belns",
      "ECCODE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/ec-code.belns",
      "FPLX": "https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/terminology/a5b84013a08880975ca84f40999e4404b14a97e2/external/go-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc-names.belns",
      "HGNCGENEFAMILY": "https://raw.githubusercontent.com/pharmacome/terminology/73688d6dc24e309fca59a1340dc9ee971e9f3baa/external/hgnc.genefamily-names.belns",
      "INTERPRO": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/interpro-names.belns",
      "MESH": "https://raw.githubusercontent.com/pharmacome/terminology/01c9daa61012b37dd0a1bc962521ba51a15b38f1/external/mesh-names.belns",
      "MGI": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/mgi-names.belns",
      "MIRBASE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/mirbase-names.belns",
      "NCBIGENE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/entrez.belns",
      "PFAM": "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/pfam-names.belns",
      "RGD": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/rgd-names.belns"
    },
    "path": "pp2a/torrent2012.bel",
    "pybel_version": "0.14.10"
  },
  "links": [
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "The excessive accumulation of phosphate groups in tau is associated with its altered capacity in promoting microtubule assembly  and  stability  [4-6].",
      "key": "a94901dc5d0c01625bc3bb2aca77f954",
      "line": 80,
      "relation": "decreases",
      "source": 27,
      "target": 9
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": " Studies  in  transgenic  mice  and  in  cell  cultures  have shown a connection between PP2A loss of function and tau hyper-phosphorylation  and  aggregation  into  PHF. ",
      "key": "5b0d664e0d3520dab5ba087e7f804785",
      "line": 131,
      "object": {
        "modifier": "Activity"
      },
      "relation": "negativeCorrelation",
      "source": 27,
      "target": 16
    },
    {
      "key": "b5ef526ab5a17da51fd96bb875e02aac",
      "relation": "hasVariant",
      "source": 26,
      "target": 27
    },
    {
      "key": "364738cb6454f2d4ec1c741ffa0b5866",
      "relation": "partOf",
      "source": 26,
      "target": 13
    },
    {
      "key": "ed64f6f261cfc8877aa67011f6730b15",
      "relation": "hasVariant",
      "source": 26,
      "target": 37
    },
    {
      "key": "14813b3527d2fc53d812f3713550ad5e",
      "relation": "hasVariant",
      "source": 26,
      "target": 31
    },
    {
      "key": "6a2b11e3af4364389963d37a85ede3ca",
      "relation": "hasVariant",
      "source": 26,
      "target": 35
    },
    {
      "key": "0481f5e01ade56c86883ceb5e0c7c930",
      "relation": "hasVariant",
      "source": 26,
      "target": 28
    },
    {
      "key": "ad1be30c6afe7368ba26966e10eeeefe",
      "relation": "hasVariant",
      "source": 26,
      "target": 29
    },
    {
      "key": "0e0ec3a09e8df8d002dd41b58ef30e38",
      "relation": "hasVariant",
      "source": 26,
      "target": 30
    },
    {
      "key": "deebc6415a1d74c0501fe5fae6165d64",
      "relation": "hasVariant",
      "source": 26,
      "target": 33
    },
    {
      "key": "e9808fec4b7de2906ee3a9ab9d1ef29e",
      "relation": "hasVariant",
      "source": 26,
      "target": 34
    },
    {
      "key": "0b23e783b6df6bf81703fab83a2f8726",
      "relation": "hasVariant",
      "source": 26,
      "target": 36
    },
    {
      "key": "66a0ff7d5f221b0d68cbc5dbafef81f5",
      "relation": "hasVariant",
      "source": 26,
      "target": 32
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "PP2A is mainly pre- sent as a soluble protein in the cytosol but it is also encoun- tered  in  the  nucleus,  mitochondria,  cytoskeleton,  and  mem- branes. ",
      "key": "0b1f65328b73332cdf3861621e551084",
      "line": 88,
      "relation": "association",
      "source": 16,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "PP2A is mainly pre- sent as a soluble protein in the cytosol but it is also encoun- tered  in  the  nucleus,  mitochondria,  cytoskeleton,  and  mem- branes. ",
      "key": "304d6b6b0c7b57d3a72d230e866f66fe",
      "line": 89,
      "relation": "association",
      "source": 16,
      "target": 3
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "PP2A is mainly pre- sent as a soluble protein in the cytosol but it is also encoun- tered  in  the  nucleus,  mitochondria,  cytoskeleton,  and  mem- branes. ",
      "key": "7632bc598b33abb36c14c19b7e23da25",
      "line": 90,
      "relation": "association",
      "source": 16,
      "target": 8
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "PP2A is mainly pre- sent as a soluble protein in the cytosol but it is also encoun- tered  in  the  nucleus,  mitochondria,  cytoskeleton,  and  mem- branes. ",
      "key": "4b0fdd3a2e50676da26851ca8d18cf84",
      "line": 91,
      "relation": "association",
      "source": 16,
      "target": 6
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "PP2A is mainly pre- sent as a soluble protein in the cytosol but it is also encoun- tered  in  the  nucleus,  mitochondria,  cytoskeleton,  and  mem- branes. ",
      "key": "d1d94a5c6b13a6975629e84b71f2e554",
      "line": 92,
      "relation": "association",
      "source": 16,
      "target": 2
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "So far, the most explored pathologies in which PP2A is implicated are cancer, and some viral and parasitic diseases [44].  More  recently,  PP2A  has  been  investigated  in  FTLD linked to mutations in the tau gene [45]. ",
      "key": "922c6edefe75070db44b38ca1f8e603f",
      "line": 120,
      "relation": "association",
      "source": 16,
      "target": 45
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "So far, the most explored pathologies in which PP2A is implicated are cancer, and some viral and parasitic diseases [44].  More  recently,  PP2A  has  been  investigated  in  FTLD linked to mutations in the tau gene [45]. ",
      "key": "620971952a18a6917479f84dc218b609",
      "line": 121,
      "relation": "association",
      "source": 16,
      "target": 44
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": " Studies  in  transgenic  mice  and  in  cell  cultures  have shown a connection between PP2A loss of function and tau hyper-phosphorylation  and  aggregation  into  PHF. ",
      "key": "f22018fee940831822cee7f842d23ff6",
      "line": 131,
      "relation": "negativeCorrelation",
      "source": 16,
      "subject": {
        "modifier": "Activity"
      },
      "target": 27
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": " Studies  in  transgenic  mice  and  in  cell  cultures  have shown a connection between PP2A loss of function and tau hyper-phosphorylation  and  aggregation  into  PHF. ",
      "key": "8854841cb173d692d8934d21bcf39e61",
      "line": 132,
      "relation": "negativeCorrelation",
      "source": 16,
      "subject": {
        "modifier": "Activity"
      },
      "target": 1
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "Trans- genic  mice  with  reduced  PP2A  activity  show  increased  tau phosphorylation  at  Ser202/Thr205  and  Ser42  [46]. ",
      "key": "86f020905fcd67682336145419706aa1",
      "line": 141,
      "relation": "decreases",
      "source": 16,
      "subject": {
        "modifier": "Activity"
      },
      "target": 31
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "Trans- genic  mice  with  reduced  PP2A  activity  show  increased  tau phosphorylation  at  Ser202/Thr205  and  Ser42  [46]. ",
      "key": "980fd34af1c06dac65987994401f29e5",
      "line": 142,
      "relation": "decreases",
      "source": 16,
      "subject": {
        "modifier": "Activity"
      },
      "target": 35
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "Moreover,  some  tau  kinases  as  cyclin- dependent  kinase  5  (cdk5)  and  TPKI  (thiamine  pyrophos- phokinase 1)/GSK3\u0002 (glycogen synthase kinase 3) are acti- vated following PP2A inhibition in starved mice [51].",
      "key": "2982d59201e2a093aa63b92ab7d3c437",
      "line": 195,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 16,
      "subject": {
        "modifier": "Activity"
      },
      "target": 23
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "Moreover,  some  tau  kinases  as  cyclin- dependent  kinase  5  (cdk5)  and  TPKI  (thiamine  pyrophos- phokinase 1)/GSK3\u0002 (glycogen synthase kinase 3) are acti- vated following PP2A inhibition in starved mice [51].",
      "key": "b23aae5e0572d1121427fa5590077556",
      "line": 196,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 16,
      "subject": {
        "modifier": "Activity"
      },
      "target": 41
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "Moreover,  some  tau  kinases  as  cyclin- dependent  kinase  5  (cdk5)  and  TPKI  (thiamine  pyrophos- phokinase 1)/GSK3\u0002 (glycogen synthase kinase 3) are acti- vated following PP2A inhibition in starved mice [51].",
      "key": "fcf7b61564c8894e06ade091b4e197fd",
      "line": 197,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 16,
      "subject": {
        "modifier": "Activity"
      },
      "target": 24
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Frontal Lobe": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "Several observations showing reduced PP2A activity by 30% in the frontal cortex in AD [55], were followed by a number of studies of PP2A mRNA and proteins.",
      "key": "8af51256eb2670f6a655ac00eb9130be",
      "line": 206,
      "relation": "negativeCorrelation",
      "source": 16,
      "subject": {
        "modifier": "Activity"
      },
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Brain": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "To sum up, PP2A activity  is  decreased  in  brain  of  AD,  as  revealed  by  using different  approaches  in  different  laboratories. ",
      "key": "8aca1b0570c666c3bb70473ccb164149",
      "line": 316,
      "relation": "negativeCorrelation",
      "source": 16,
      "subject": {
        "modifier": "Activity"
      },
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "Decreased  of PP2A, but not of other phosphatases, has also been observed in Down syndrome correlating with increased tau pathology. ",
      "key": "19c5fe322d3c992ca2b1e91d090c5e66",
      "line": 251,
      "relation": "negativeCorrelation",
      "source": 16,
      "target": 43
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "PP2A is mainly pre- sent as a soluble protein in the cytosol but it is also encoun- tered  in  the  nucleus,  mitochondria,  cytoskeleton,  and  mem- branes. ",
      "key": "6049abdb9d7856117339fc9dc561a003",
      "line": 88,
      "relation": "association",
      "source": 7,
      "target": 16
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "PP2A is mainly pre- sent as a soluble protein in the cytosol but it is also encoun- tered  in  the  nucleus,  mitochondria,  cytoskeleton,  and  mem- branes. ",
      "key": "50313734a04f6ad7cffcfc6bf2980ead",
      "line": 89,
      "relation": "association",
      "source": 3,
      "target": 16
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "PP2A is mainly pre- sent as a soluble protein in the cytosol but it is also encoun- tered  in  the  nucleus,  mitochondria,  cytoskeleton,  and  mem- branes. ",
      "key": "5e6ab81d086ce581c3ae5c0fec502daf",
      "line": 90,
      "relation": "association",
      "source": 8,
      "target": 16
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "PP2A is mainly pre- sent as a soluble protein in the cytosol but it is also encoun- tered  in  the  nucleus,  mitochondria,  cytoskeleton,  and  mem- branes. ",
      "key": "b4261f6bcc9d12b42b4c8e4f45a4a2b1",
      "line": 91,
      "relation": "association",
      "source": 6,
      "target": 16
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "PP2A is mainly pre- sent as a soluble protein in the cytosol but it is also encoun- tered  in  the  nucleus,  mitochondria,  cytoskeleton,  and  mem- branes. ",
      "key": "176f32ee77609ebba703ed4d83b38eaf",
      "line": 92,
      "relation": "association",
      "source": 2,
      "target": 16
    },
    {
      "key": "84d1533cb683183daa7689a3fab5c04d",
      "relation": "partOf",
      "source": 17,
      "target": 16
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "Analyses of protein expression by using gel electrophore- sis and western blotting have shown not only a reduction of PP2A  C  expression  levels  but  also  a  marked  reduction  of B55\u0001, thus indicating that PP2A impairment is the result of combined  effects  of  different  subunits  [60].",
      "key": "eb71e61adbdb86a19ace243d6d7760b9",
      "line": 243,
      "relation": "negativeCorrelation",
      "source": 17,
      "target": 42
    },
    {
      "key": "03dcaaf1b6fdbc734c269b692a564776",
      "relation": "hasVariant",
      "source": 17,
      "target": 18
    },
    {
      "key": "c6918024e3ac6d416eebbaabe4547a3b",
      "relation": "partOf",
      "source": 17,
      "target": 12
    },
    {
      "key": "c46561756d12d1ca5927acea5b84e1c8",
      "relation": "hasVariant",
      "source": 17,
      "target": 21
    },
    {
      "key": "0b3b3bfc41408ea586920dc8b46e4ff5",
      "relation": "hasVariant",
      "source": 17,
      "target": 19
    },
    {
      "key": "4469c57ea1ff897cbd41045a2fff8043",
      "relation": "hasVariant",
      "source": 17,
      "target": 20
    },
    {
      "key": "f8767e631aba2478b03a6a7cb596e40b",
      "relation": "partOf",
      "source": 14,
      "target": 16
    },
    {
      "key": "38b3df2271b7b023ab7c4d3d20789bce",
      "relation": "partOf",
      "source": 14,
      "target": 12
    },
    {
      "key": "0c251906330c2b04e2474dc02fcdcdd9",
      "relation": "partOf",
      "source": 15,
      "target": 16
    },
    {
      "key": "7317d48f39c169977307d6736dd4e6a3",
      "relation": "partOf",
      "source": 15,
      "target": 12
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "Within the brain, ACB55\u0001 (B55\u0001) is the major PP2A B iso- form  and  it  binds  to  tau  with  high  affinity  both  in  in  vitro protein-protein  interaction  paradigms  and  in  cell  cultures [36, 37]. ",
      "key": "6cdf78f064c434cb07a6a4123137e02a",
      "line": 110,
      "relation": "association",
      "source": 39,
      "target": 5
    },
    {
      "key": "66625fa7286b859a9996d1168027b4c4",
      "relation": "partOf",
      "source": 39,
      "target": 13
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "Analyses of protein expression by using gel electrophore- sis and western blotting have shown not only a reduction of PP2A  C  expression  levels  but  also  a  marked  reduction  of B55\u0001, thus indicating that PP2A impairment is the result of combined  effects  of  different  subunits  [60].",
      "key": "283620b9db07737211bc43fe86837f72",
      "line": 244,
      "relation": "negativeCorrelation",
      "source": 39,
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "Within the brain, ACB55\u0001 (B55\u0001) is the major PP2A B iso- form  and  it  binds  to  tau  with  high  affinity  both  in  in  vitro protein-protein  interaction  paradigms  and  in  cell  cultures [36, 37]. ",
      "key": "0720569a8c2ace60efb0081295265820",
      "line": 110,
      "relation": "association",
      "source": 5,
      "target": 39
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "So far, the most explored pathologies in which PP2A is implicated are cancer, and some viral and parasitic diseases [44].  More  recently,  PP2A  has  been  investigated  in  FTLD linked to mutations in the tau gene [45]. ",
      "key": "604260e6192ef42bf0fc46fd3ca20386",
      "line": 120,
      "relation": "association",
      "source": 45,
      "target": 16
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "So far, the most explored pathologies in which PP2A is implicated are cancer, and some viral and parasitic diseases [44].  More  recently,  PP2A  has  been  investigated  in  FTLD linked to mutations in the tau gene [45]. ",
      "key": "2db7d15124980e26c727a97934dec319",
      "line": 121,
      "relation": "association",
      "source": 44,
      "target": 16
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "So far, the most explored pathologies in which PP2A is implicated are cancer, and some viral and parasitic diseases [44].  More  recently,  PP2A  has  been  investigated  in  FTLD linked to mutations in the tau gene [45]. ",
      "key": "58138e96322461cd9ef72e3400e1a2aa",
      "line": 122,
      "relation": "association",
      "source": 44,
      "target": 37
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "So far, the most explored pathologies in which PP2A is implicated are cancer, and some viral and parasitic diseases [44].  More  recently,  PP2A  has  been  investigated  in  FTLD linked to mutations in the tau gene [45]. ",
      "key": "845778650b6bcb0dc54dfdde12feb3df",
      "line": 122,
      "relation": "association",
      "source": 37,
      "target": 44
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": " Studies  in  transgenic  mice  and  in  cell  cultures  have shown a connection between PP2A loss of function and tau hyper-phosphorylation  and  aggregation  into  PHF. ",
      "key": "7ce62e78e4ee4007a27228f20157d655",
      "line": 132,
      "object": {
        "modifier": "Activity"
      },
      "relation": "negativeCorrelation",
      "source": 1,
      "target": 16
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "Similar findings have been observed in metabolically active rat brain slices, where a selective inhibition of PP2A with OA results in  an  aberrant  phosphorylation  of  tau  at  the  same  residues seen in AD brains at serines (Ser) 198, 199, 202, 396, 404, 422 and 262 [11, 47, 48].",
      "key": "ae5fc28f35faf337ef6bbfe1748dcfa8",
      "line": 156,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 0,
      "target": 16
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "Similar findings have been observed in metabolically active rat brain slices, where a selective inhibition of PP2A with OA results in  an  aberrant  phosphorylation  of  tau  at  the  same  residues seen in AD brains at serines (Ser) 198, 199, 202, 396, 404, 422 and 262 [11, 47, 48].",
      "key": "b5c0e6f0e657d94c1c6394e5de1cc78c",
      "line": 157,
      "relation": "increases",
      "source": 0,
      "target": 28
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "Similar findings have been observed in metabolically active rat brain slices, where a selective inhibition of PP2A with OA results in  an  aberrant  phosphorylation  of  tau  at  the  same  residues seen in AD brains at serines (Ser) 198, 199, 202, 396, 404, 422 and 262 [11, 47, 48].",
      "key": "7bc587bc61418564106ab2133f224380",
      "line": 158,
      "relation": "increases",
      "source": 0,
      "target": 29
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "Similar findings have been observed in metabolically active rat brain slices, where a selective inhibition of PP2A with OA results in  an  aberrant  phosphorylation  of  tau  at  the  same  residues seen in AD brains at serines (Ser) 198, 199, 202, 396, 404, 422 and 262 [11, 47, 48].",
      "key": "3573ad1d348da300344a35b20e8c2685",
      "line": 159,
      "relation": "increases",
      "source": 0,
      "target": 30
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "Similar findings have been observed in metabolically active rat brain slices, where a selective inhibition of PP2A with OA results in  an  aberrant  phosphorylation  of  tau  at  the  same  residues seen in AD brains at serines (Ser) 198, 199, 202, 396, 404, 422 and 262 [11, 47, 48].",
      "key": "7fcd4d8c13eb09a736d110ad00859429",
      "line": 160,
      "relation": "increases",
      "source": 0,
      "target": 33
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "Similar findings have been observed in metabolically active rat brain slices, where a selective inhibition of PP2A with OA results in  an  aberrant  phosphorylation  of  tau  at  the  same  residues seen in AD brains at serines (Ser) 198, 199, 202, 396, 404, 422 and 262 [11, 47, 48].",
      "key": "98e9f9707bb73030dbaa3319f38543c8",
      "line": 161,
      "relation": "increases",
      "source": 0,
      "target": 34
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "Similar findings have been observed in metabolically active rat brain slices, where a selective inhibition of PP2A with OA results in  an  aberrant  phosphorylation  of  tau  at  the  same  residues seen in AD brains at serines (Ser) 198, 199, 202, 396, 404, 422 and 262 [11, 47, 48].",
      "key": "b02fcf2a2c8e95bb1bfd1225b38977c0",
      "line": 162,
      "relation": "increases",
      "source": 0,
      "target": 36
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "Similar findings have been observed in metabolically active rat brain slices, where a selective inhibition of PP2A with OA results in  an  aberrant  phosphorylation  of  tau  at  the  same  residues seen in AD brains at serines (Ser) 198, 199, 202, 396, 404, 422 and 262 [11, 47, 48].",
      "key": "edd9898318da4a45b175367d377ac298",
      "line": 163,
      "relation": "increases",
      "source": 0,
      "target": 32
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "Further experiments based on the injection of a PP2A inhibitor in the rat hippocampus demon- strated tau hyper-phosphorylation, and learning and memory deficits  [49,  50]. ",
      "key": "9f7a1eb2f032fcfb606e46cd9b24da16",
      "line": 182,
      "relation": "increases",
      "source": 0,
      "target": 27
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "Further experiments based on the injection of a PP2A inhibitor in the rat hippocampus demon- strated tau hyper-phosphorylation, and learning and memory deficits  [49,  50]. ",
      "key": "60bf4eeaf1cdd1952d05cf71da9fa08f",
      "line": 183,
      "relation": "decreases",
      "source": 0,
      "target": 10
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "Further experiments based on the injection of a PP2A inhibitor in the rat hippocampus demon- strated tau hyper-phosphorylation, and learning and memory deficits  [49,  50]. ",
      "key": "18e0117e45253f2c703b87948ceeebf4",
      "line": 184,
      "relation": "decreases",
      "source": 0,
      "target": 11
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "Similar findings have been observed in metabolically active rat brain slices, where a selective inhibition of PP2A with OA results in  an  aberrant  phosphorylation  of  tau  at  the  same  residues seen in AD brains at serines (Ser) 198, 199, 202, 396, 404, 422 and 262 [11, 47, 48].",
      "key": "13f6919556d76ee4a0fa4d3d23f00fc5",
      "line": 164,
      "relation": "positiveCorrelation",
      "source": 28,
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "Similar findings have been observed in metabolically active rat brain slices, where a selective inhibition of PP2A with OA results in  an  aberrant  phosphorylation  of  tau  at  the  same  residues seen in AD brains at serines (Ser) 198, 199, 202, 396, 404, 422 and 262 [11, 47, 48].",
      "key": "52030829edc98db20cf72a7233112926",
      "line": 165,
      "relation": "positiveCorrelation",
      "source": 29,
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "Similar findings have been observed in metabolically active rat brain slices, where a selective inhibition of PP2A with OA results in  an  aberrant  phosphorylation  of  tau  at  the  same  residues seen in AD brains at serines (Ser) 198, 199, 202, 396, 404, 422 and 262 [11, 47, 48].",
      "key": "8cf6ebe807ebd6905b392e9a2433b3a8",
      "line": 166,
      "relation": "positiveCorrelation",
      "source": 30,
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "Similar findings have been observed in metabolically active rat brain slices, where a selective inhibition of PP2A with OA results in  an  aberrant  phosphorylation  of  tau  at  the  same  residues seen in AD brains at serines (Ser) 198, 199, 202, 396, 404, 422 and 262 [11, 47, 48].",
      "key": "b4b25f962a9fc67c972b35519dd88271",
      "line": 167,
      "relation": "positiveCorrelation",
      "source": 33,
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "Similar findings have been observed in metabolically active rat brain slices, where a selective inhibition of PP2A with OA results in  an  aberrant  phosphorylation  of  tau  at  the  same  residues seen in AD brains at serines (Ser) 198, 199, 202, 396, 404, 422 and 262 [11, 47, 48].",
      "key": "9859009a5f65054b51b2be5b8511f089",
      "line": 168,
      "relation": "positiveCorrelation",
      "source": 34,
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "Similar findings have been observed in metabolically active rat brain slices, where a selective inhibition of PP2A with OA results in  an  aberrant  phosphorylation  of  tau  at  the  same  residues seen in AD brains at serines (Ser) 198, 199, 202, 396, 404, 422 and 262 [11, 47, 48].",
      "key": "6dab777a8bdf9e727853116c25553da5",
      "line": 169,
      "relation": "positiveCorrelation",
      "source": 36,
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "Similar findings have been observed in metabolically active rat brain slices, where a selective inhibition of PP2A with OA results in  an  aberrant  phosphorylation  of  tau  at  the  same  residues seen in AD brains at serines (Ser) 198, 199, 202, 396, 404, 422 and 262 [11, 47, 48].",
      "key": "b072c09198c6e2cdbe0556a90cd570c7",
      "line": 170,
      "relation": "positiveCorrelation",
      "source": 32,
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "Similar findings have been observed in metabolically active rat brain slices, where a selective inhibition of PP2A with OA results in  an  aberrant  phosphorylation  of  tau  at  the  same  residues seen in AD brains at serines (Ser) 198, 199, 202, 396, 404, 422 and 262 [11, 47, 48].",
      "key": "faea34692a18a66273339d5e450efab9",
      "line": 164,
      "relation": "positiveCorrelation",
      "source": 42,
      "target": 28
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "Similar findings have been observed in metabolically active rat brain slices, where a selective inhibition of PP2A with OA results in  an  aberrant  phosphorylation  of  tau  at  the  same  residues seen in AD brains at serines (Ser) 198, 199, 202, 396, 404, 422 and 262 [11, 47, 48].",
      "key": "897b256d224e8120bc7a748c3d628613",
      "line": 165,
      "relation": "positiveCorrelation",
      "source": 42,
      "target": 29
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "Similar findings have been observed in metabolically active rat brain slices, where a selective inhibition of PP2A with OA results in  an  aberrant  phosphorylation  of  tau  at  the  same  residues seen in AD brains at serines (Ser) 198, 199, 202, 396, 404, 422 and 262 [11, 47, 48].",
      "key": "f0d091076950fbec3eccf8183abbce39",
      "line": 166,
      "relation": "positiveCorrelation",
      "source": 42,
      "target": 30
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "Similar findings have been observed in metabolically active rat brain slices, where a selective inhibition of PP2A with OA results in  an  aberrant  phosphorylation  of  tau  at  the  same  residues seen in AD brains at serines (Ser) 198, 199, 202, 396, 404, 422 and 262 [11, 47, 48].",
      "key": "ab1f949b36ff407f7dd42832bb1563a9",
      "line": 167,
      "relation": "positiveCorrelation",
      "source": 42,
      "target": 33
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "Similar findings have been observed in metabolically active rat brain slices, where a selective inhibition of PP2A with OA results in  an  aberrant  phosphorylation  of  tau  at  the  same  residues seen in AD brains at serines (Ser) 198, 199, 202, 396, 404, 422 and 262 [11, 47, 48].",
      "key": "eab52c36ad5b010b4637e451ae1ebd88",
      "line": 168,
      "relation": "positiveCorrelation",
      "source": 42,
      "target": 34
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "Similar findings have been observed in metabolically active rat brain slices, where a selective inhibition of PP2A with OA results in  an  aberrant  phosphorylation  of  tau  at  the  same  residues seen in AD brains at serines (Ser) 198, 199, 202, 396, 404, 422 and 262 [11, 47, 48].",
      "key": "acdf2fe638dd2e7debda7ff930885b4e",
      "line": 169,
      "relation": "positiveCorrelation",
      "source": 42,
      "target": 36
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "Similar findings have been observed in metabolically active rat brain slices, where a selective inhibition of PP2A with OA results in  an  aberrant  phosphorylation  of  tau  at  the  same  residues seen in AD brains at serines (Ser) 198, 199, 202, 396, 404, 422 and 262 [11, 47, 48].",
      "key": "291fbd991a22e0d6bf8decb1f2820fd9",
      "line": 170,
      "relation": "positiveCorrelation",
      "source": 42,
      "target": 32
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Frontal Lobe": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "Several observations showing reduced PP2A activity by 30% in the frontal cortex in AD [55], were followed by a number of studies of PP2A mRNA and proteins.",
      "key": "c62974c2cb82888312c5bf207ddb3826",
      "line": 206,
      "object": {
        "modifier": "Activity"
      },
      "relation": "negativeCorrelation",
      "source": 42,
      "target": 16
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Brain": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "To sum up, PP2A activity  is  decreased  in  brain  of  AD,  as  revealed  by  using different  approaches  in  different  laboratories. ",
      "key": "b98fd59ee6de8f668ddbc683a8ac4468",
      "line": 316,
      "object": {
        "modifier": "Activity"
      },
      "relation": "negativeCorrelation",
      "source": 42,
      "target": 16
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "CA3 Region, Hippocampal": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": " Decreased mRNA  levels  of  PP2A  C  have  been  reported  in  the  CA3 region  of  AD  hippocampus  by  in  situ  RNA  hybridisation [56].  Moreover,  microarray  RNA  analysis  carried  out  to compare  the  expression  of  more  than  7,000  gene  in  the amygdala,  cingulate  cortex,  striatum  and  cerebellum  dis- closed down-regulation of the catalytic subunit PP2A C\u0001 in AD [57]. This has been further corroborated by quantitative TaqMan PCR showing reduced PP2A C\u0001 mRNA expression levels  in  the  hippocampus,  but  not  in  the  frontal  cortex,  in AD  cases  with  disease  progression  Fig.  (1).",
      "key": "8fd5fd6a71f465880b103fe898683d1a",
      "line": 225,
      "relation": "negativeCorrelation",
      "source": 42,
      "target": 46
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Frontal Lobe": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": " Decreased mRNA  levels  of  PP2A  C  have  been  reported  in  the  CA3 region  of  AD  hippocampus  by  in  situ  RNA  hybridisation [56].  Moreover,  microarray  RNA  analysis  carried  out  to compare  the  expression  of  more  than  7,000  gene  in  the amygdala,  cingulate  cortex,  striatum  and  cerebellum  dis- closed down-regulation of the catalytic subunit PP2A C\u0001 in AD [57]. This has been further corroborated by quantitative TaqMan PCR showing reduced PP2A C\u0001 mRNA expression levels  in  the  hippocampus,  but  not  in  the  frontal  cortex,  in AD  cases  with  disease  progression  Fig.  (1).",
      "key": "82cfdd9b0cb61bf6a8f51ff68df80b24",
      "line": 233,
      "relation": "causesNoChange",
      "source": 42,
      "target": 46
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "CA3 Region, Hippocampal": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": " Decreased mRNA  levels  of  PP2A  C  have  been  reported  in  the  CA3 region  of  AD  hippocampus  by  in  situ  RNA  hybridisation [56].  Moreover,  microarray  RNA  analysis  carried  out  to compare  the  expression  of  more  than  7,000  gene  in  the amygdala,  cingulate  cortex,  striatum  and  cerebellum  dis- closed down-regulation of the catalytic subunit PP2A C\u0001 in AD [57]. This has been further corroborated by quantitative TaqMan PCR showing reduced PP2A C\u0001 mRNA expression levels  in  the  hippocampus,  but  not  in  the  frontal  cortex,  in AD  cases  with  disease  progression  Fig.  (1).",
      "key": "a4dfba85856848a385ad6eb30f6070ff",
      "line": 226,
      "relation": "negativeCorrelation",
      "source": 42,
      "target": 47
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "Analyses of protein expression by using gel electrophore- sis and western blotting have shown not only a reduction of PP2A  C  expression  levels  but  also  a  marked  reduction  of B55\u0001, thus indicating that PP2A impairment is the result of combined  effects  of  different  subunits  [60].",
      "key": "55948909793cdd77a0ea3bf3e1f11075",
      "line": 243,
      "relation": "negativeCorrelation",
      "source": 42,
      "target": 17
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "Analyses of protein expression by using gel electrophore- sis and western blotting have shown not only a reduction of PP2A  C  expression  levels  but  also  a  marked  reduction  of B55\u0001, thus indicating that PP2A impairment is the result of combined  effects  of  different  subunits  [60].",
      "key": "c0259f13f21862e7b6eda3afc6b0b367",
      "line": 244,
      "relation": "negativeCorrelation",
      "source": 42,
      "target": 39
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": " PP2A  C methylation  at  Leu309  is  reduced  in  AD  and  this  seems  to contribute to PP2A C dysfunction by impairing the assembly of the trimer [77, 78]. ",
      "key": "c4bfe6b49657a4a684f6453da282f22e",
      "line": 279,
      "relation": "negativeCorrelation",
      "source": 42,
      "target": 19
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": " Complementing these findings, immu- nohistochemical  and  western  blot  studies  have  shown  re- duced  expression  of  PPMT  [77],  and  up-regulation  of  the PP2A inhibitors I 1  and I 2  in AD cases [79, 80]. ",
      "key": "99f8095a003f1148cb8e20556a6c7c97",
      "line": 289,
      "relation": "negativeCorrelation",
      "source": 42,
      "target": 25
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": " Complementing these findings, immu- nohistochemical  and  western  blot  studies  have  shown  re- duced  expression  of  PPMT  [77],  and  up-regulation  of  the PP2A inhibitors I 1  and I 2  in AD cases [79, 80]. ",
      "key": "c78ccb9e16d8e70e6419d71c8c6bdbe7",
      "line": 292,
      "relation": "positiveCorrelation",
      "source": 42,
      "target": 22
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": " Complementing these findings, immu- nohistochemical  and  western  blot  studies  have  shown  re- duced  expression  of  PPMT  [77],  and  up-regulation  of  the PP2A inhibitors I 1  and I 2  in AD cases [79, 80]. ",
      "key": "79111cdbf58c70bad975f3d3fda307fe",
      "line": 293,
      "relation": "positiveCorrelation",
      "source": 42,
      "target": 40
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Entorhinal Cortex": true,
          "Frontal Lobe": true,
          "Hippocampus": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": " High  levels  of  PP2A  C  phosphorylated  at  Tyr307  have been  reported  in  the  entorhinal  cortex,  hippocampus  and frontal cortex in AD compared to controls [81].",
      "key": "de6109f528fc0e7b270f4592b4799164",
      "line": 301,
      "relation": "positiveCorrelation",
      "source": 42,
      "target": 21
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "CA3 Region, Hippocampal": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": " Decreased mRNA  levels  of  PP2A  C  have  been  reported  in  the  CA3 region  of  AD  hippocampus  by  in  situ  RNA  hybridisation [56].  Moreover,  microarray  RNA  analysis  carried  out  to compare  the  expression  of  more  than  7,000  gene  in  the amygdala,  cingulate  cortex,  striatum  and  cerebellum  dis- closed down-regulation of the catalytic subunit PP2A C\u0001 in AD [57]. This has been further corroborated by quantitative TaqMan PCR showing reduced PP2A C\u0001 mRNA expression levels  in  the  hippocampus,  but  not  in  the  frontal  cortex,  in AD  cases  with  disease  progression  Fig.  (1).",
      "key": "ce885da7824ae0eba35a96be574cde05",
      "line": 225,
      "relation": "negativeCorrelation",
      "source": 46,
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "CA3 Region, Hippocampal": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": " Decreased mRNA  levels  of  PP2A  C  have  been  reported  in  the  CA3 region  of  AD  hippocampus  by  in  situ  RNA  hybridisation [56].  Moreover,  microarray  RNA  analysis  carried  out  to compare  the  expression  of  more  than  7,000  gene  in  the amygdala,  cingulate  cortex,  striatum  and  cerebellum  dis- closed down-regulation of the catalytic subunit PP2A C\u0001 in AD [57]. This has been further corroborated by quantitative TaqMan PCR showing reduced PP2A C\u0001 mRNA expression levels  in  the  hippocampus,  but  not  in  the  frontal  cortex,  in AD  cases  with  disease  progression  Fig.  (1).",
      "key": "9e9ad6926c557122a40040c7c1a41d87",
      "line": 226,
      "relation": "negativeCorrelation",
      "source": 47,
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "Decreased  of PP2A, but not of other phosphatases, has also been observed in Down syndrome correlating with increased tau pathology. ",
      "key": "d46497716142b0f3cb05e19a4b95413a",
      "line": 251,
      "relation": "negativeCorrelation",
      "source": 43,
      "target": 16
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": " Car- boxyl  methylation  of  the  catalytic  subunit  is  required  for efficient in vivo assembly of the trimer C, A, and B\u0001 [63-65]; a process that is balanced by the opposite actions of methyl- transferase  type  IV  (PPMT)  and  the  methylesterase  PME-1 [66-70]. ",
      "key": "eb07b0c84ef5514bf2127ad3b7850d56",
      "line": 262,
      "relation": "increases",
      "source": 18,
      "target": 12
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": " Car- boxyl  methylation  of  the  catalytic  subunit  is  required  for efficient in vivo assembly of the trimer C, A, and B\u0001 [63-65]; a process that is balanced by the opposite actions of methyl- transferase  type  IV  (PPMT)  and  the  methylesterase  PME-1 [66-70]. ",
      "key": "456e243b6b576959e55b72aed16954c2",
      "line": 263,
      "relation": "increases",
      "source": 25,
      "target": 18
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": " Complementing these findings, immu- nohistochemical  and  western  blot  studies  have  shown  re- duced  expression  of  PPMT  [77],  and  up-regulation  of  the PP2A inhibitors I 1  and I 2  in AD cases [79, 80]. ",
      "key": "6b2fadfdfbbd2e44739b1821f05cffb0",
      "line": 289,
      "relation": "negativeCorrelation",
      "source": 25,
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": " Car- boxyl  methylation  of  the  catalytic  subunit  is  required  for efficient in vivo assembly of the trimer C, A, and B\u0001 [63-65]; a process that is balanced by the opposite actions of methyl- transferase  type  IV  (PPMT)  and  the  methylesterase  PME-1 [66-70]. ",
      "key": "6d94ee459a3fc7e77837559ccf29880d",
      "line": 264,
      "relation": "decreases",
      "source": 38,
      "target": 18
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "The other important post-translational modi- fication is phosphorylation of PP2A C at Tyr307 which in- hibits PP2A activity [74-76]. ",
      "key": "71e9c9ac9acac0c6c421f6c77b835ed9",
      "line": 271,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 21,
      "target": 16
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Entorhinal Cortex": true,
          "Frontal Lobe": true,
          "Hippocampus": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": " High  levels  of  PP2A  C  phosphorylated  at  Tyr307  have been  reported  in  the  entorhinal  cortex,  hippocampus  and frontal cortex in AD compared to controls [81].",
      "key": "822caa54bd6cfbf7f957ee23d5843572",
      "line": 301,
      "relation": "positiveCorrelation",
      "source": 21,
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": " PP2A  C methylation  at  Leu309  is  reduced  in  AD  and  this  seems  to contribute to PP2A C dysfunction by impairing the assembly of the trimer [77, 78]. ",
      "key": "04a654872b020bfddcffd28d16b49018",
      "line": 279,
      "relation": "negativeCorrelation",
      "source": 19,
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": " PP2A  C methylation  at  Leu309  is  reduced  in  AD  and  this  seems  to contribute to PP2A C dysfunction by impairing the assembly of the trimer [77, 78]. ",
      "key": "13f2d075d7b532b0277f87356da2d0fd",
      "line": 280,
      "relation": "decreases",
      "source": 19,
      "target": 12
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": " Complementing these findings, immu- nohistochemical  and  western  blot  studies  have  shown  re- duced  expression  of  PPMT  [77],  and  up-regulation  of  the PP2A inhibitors I 1  and I 2  in AD cases [79, 80]. ",
      "key": "2afa9cd92b6cfb3198e50468211a9c58",
      "line": 290,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 22,
      "target": 16
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": " Complementing these findings, immu- nohistochemical  and  western  blot  studies  have  shown  re- duced  expression  of  PPMT  [77],  and  up-regulation  of  the PP2A inhibitors I 1  and I 2  in AD cases [79, 80]. ",
      "key": "5e6bcebf413b056b1806980c319453f0",
      "line": 292,
      "relation": "positiveCorrelation",
      "source": 22,
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": " Complementing these findings, immu- nohistochemical  and  western  blot  studies  have  shown  re- duced  expression  of  PPMT  [77],  and  up-regulation  of  the PP2A inhibitors I 1  and I 2  in AD cases [79, 80]. ",
      "key": "cba197bf7a8d25deade939184c4e83ba",
      "line": 291,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 40,
      "target": 16
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": " Complementing these findings, immu- nohistochemical  and  western  blot  studies  have  shown  re- duced  expression  of  PPMT  [77],  and  up-regulation  of  the PP2A inhibitors I 1  and I 2  in AD cases [79, 80]. ",
      "key": "362ac266dbb2bb4d412c38e0ac1de89f",
      "line": 293,
      "relation": "positiveCorrelation",
      "source": 40,
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "Furthermore, phosphorylated  PP2A  C  decorates  neurofibrillary  tangles. ",
      "key": "543f221408c3ee43c9fac64105919efe",
      "line": 308,
      "relation": "association",
      "source": 20,
      "target": 4
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ferrer I",
          "Torrent L"
        ],
        "date": "2012-02-01",
        "db": "PubMed",
        "db_id": "22299660",
        "db_name": "PP2A and Alzheimer disease.",
        "first": "Torrent L",
        "journal": "Current Alzheimer research",
        "last": "Ferrer I",
        "pages": "248-56",
        "volume": "9"
      },
      "evidence": "Furthermore, phosphorylated  PP2A  C  decorates  neurofibrillary  tangles. ",
      "key": "febb7fb325051b8fc47fa54d3b52906c",
      "line": 308,
      "relation": "association",
      "source": 4,
      "target": 20
    }
  ],
  "multigraph": true,
  "nodes": [
    {
      "bel": "a(CHEBI:\"okadaic acid\")",
      "concept": {
        "name": "okadaic acid",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "7877fd31588d4b98904a3049d15e0c9b"
    },
    {
      "bel": "a(CONSO:\"paired helical filaments\")",
      "concept": {
        "name": "paired helical filaments",
        "namespace": "CONSO"
      },
      "function": "Abundance",
      "id": "cf5d166157778ce378f93f26ae7c2f3c"
    },
    {
      "bel": "a(MESH:\"Cell Membrane\")",
      "concept": {
        "name": "Cell Membrane",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "5f1f124138addc7af92d1beca50bdbd4"
    },
    {
      "bel": "a(MESH:\"Cell Nucleus\")",
      "concept": {
        "name": "Cell Nucleus",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "2bfbd49d58fe7ecad2033766ac469284"
    },
    {
      "bel": "a(MESH:\"Neurofibrillary Tangles\")",
      "concept": {
        "name": "Neurofibrillary Tangles",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "1ea09b7aace0ed3a0da3f815bd92b304"
    },
    {
      "bel": "a(MESH:Brain)",
      "concept": {
        "name": "Brain",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "122591e1e5a28ece8ac1124593ee701f"
    },
    {
      "bel": "a(MESH:Cytoskeleton)",
      "concept": {
        "name": "Cytoskeleton",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "0e4d0b021771899e4e5087eb6ced2278"
    },
    {
      "bel": "a(MESH:Cytosol)",
      "concept": {
        "name": "Cytosol",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "31427f87550747e8e4f9d903c47146b9"
    },
    {
      "bel": "a(MESH:Mitochondria)",
      "concept": {
        "name": "Mitochondria",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "da073a8aacb1ab0764fce04ee8bbb54f"
    },
    {
      "bel": "bp(GO:\"microtubule polymerization\")",
      "concept": {
        "name": "microtubule polymerization",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "689df6bb44a41b81144f3915d73a445a"
    },
    {
      "bel": "bp(GO:learning)",
      "concept": {
        "name": "learning",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "75fc4f4e732353b87f83a4a8174ffb29"
    },
    {
      "bel": "bp(GO:memory)",
      "concept": {
        "name": "memory",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "e03a718b44a1ff30acea5c31966879a9"
    },
    {
      "bel": "complex(p(FPLX:\"PPP2R_A\"), p(FPLX:\"PPP2R_B\"), p(FPLX:PPP2C))",
      "function": "Complex",
      "id": "41afc15824c8ef27663f29bf8ddb2bf2",
      "members": [
        {
          "bel": "p(FPLX:\"PPP2R_A\")",
          "concept": {
            "name": "PPP2R_A",
            "namespace": "FPLX"
          },
          "function": "Protein",
          "id": "9523e6c134c92fbdf576bd9747e3ac38"
        },
        {
          "bel": "p(FPLX:\"PPP2R_B\")",
          "concept": {
            "name": "PPP2R_B",
            "namespace": "FPLX"
          },
          "function": "Protein",
          "id": "986c4d9a0545ee85d2b7ea287518acde"
        },
        {
          "bel": "p(FPLX:PPP2C)",
          "concept": {
            "name": "PPP2C",
            "namespace": "FPLX"
          },
          "function": "Protein",
          "id": "4f376d935dc5954e01ef1b7d269cade6"
        }
      ]
    },
    {
      "bel": "complex(p(HGNC:MAPT), p(HGNC:PPP2R2A))",
      "function": "Complex",
      "id": "3e0bfd680b7ddecbd491ba75f6899657",
      "members": [
        {
          "bel": "p(HGNC:MAPT)",
          "concept": {
            "name": "MAPT",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "7d1009217050e75d549c8c5aa83309a8"
        },
        {
          "bel": "p(HGNC:PPP2R2A)",
          "concept": {
            "name": "PPP2R2A",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "e44251a05a824325cdf1dbb55dc62950"
        }
      ]
    },
    {
      "bel": "p(FPLX:\"PPP2R_A\")",
      "concept": {
        "name": "PPP2R_A",
        "namespace": "FPLX"
      },
      "function": "Protein",
      "id": "9523e6c134c92fbdf576bd9747e3ac38"
    },
    {
      "bel": "p(FPLX:\"PPP2R_B\")",
      "concept": {
        "name": "PPP2R_B",
        "namespace": "FPLX"
      },
      "function": "Protein",
      "id": "986c4d9a0545ee85d2b7ea287518acde"
    },
    {
      "bel": "p(FPLX:PPP2)",
      "concept": {
        "name": "PPP2",
        "namespace": "FPLX"
      },
      "function": "Protein",
      "id": "366ec44be4bbd8d4b72b6829c348c1f8"
    },
    {
      "bel": "p(FPLX:PPP2C)",
      "concept": {
        "name": "PPP2C",
        "namespace": "FPLX"
      },
      "function": "Protein",
      "id": "4f376d935dc5954e01ef1b7d269cade6"
    },
    {
      "bel": "p(FPLX:PPP2C, pmod(Me))",
      "concept": {
        "name": "PPP2C",
        "namespace": "FPLX"
      },
      "function": "Protein",
      "id": "5ae01fd9a7a4da1d36f1be1f235353ac",
      "variants": [
        {
          "concept": {
            "name": "Me",
            "namespace": "bel"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(FPLX:PPP2C, pmod(Me, Leu, 309))",
      "concept": {
        "name": "PPP2C",
        "namespace": "FPLX"
      },
      "function": "Protein",
      "id": "b504b9e7a41a4ad561681f647e1a6939",
      "variants": [
        {
          "code": "Leu",
          "concept": {
            "name": "Me",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 309
        }
      ]
    },
    {
      "bel": "p(FPLX:PPP2C, pmod(Ph))",
      "concept": {
        "name": "PPP2C",
        "namespace": "FPLX"
      },
      "function": "Protein",
      "id": "b7bad48f1114daa446f43b3833685bbd",
      "variants": [
        {
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(FPLX:PPP2C, pmod(Ph, Tyr, 307))",
      "concept": {
        "name": "PPP2C",
        "namespace": "FPLX"
      },
      "function": "Protein",
      "id": "f0ad8fa50b9ed36ffee7e2905d527b3b",
      "variants": [
        {
          "code": "Tyr",
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 307
        }
      ]
    },
    {
      "bel": "p(HGNC:ANP32A)",
      "concept": {
        "name": "ANP32A",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "2608a6e64cad7a963f5423d3fa7e9308"
    },
    {
      "bel": "p(HGNC:CDK5)",
      "concept": {
        "name": "CDK5",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "cb1e1b28f1d3fe30db837d601f26fe1b"
    },
    {
      "bel": "p(HGNC:GSK3B)",
      "concept": {
        "name": "GSK3B",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "8eaf29c9e491ff4e49619e77de92467c"
    },
    {
      "bel": "p(HGNC:ICMT)",
      "concept": {
        "name": "ICMT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "70215df805387b489a262eab0de057e3"
    },
    {
      "bel": "p(HGNC:MAPT)",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "7d1009217050e75d549c8c5aa83309a8"
    },
    {
      "bel": "p(HGNC:MAPT, pmod(CONSO:hyperphosphorylation))",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "0d2d8072f03dcdf148e658067d37b9cb",
      "variants": [
        {
          "concept": {
            "name": "hyperphosphorylation",
            "namespace": "CONSO"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT, pmod(Ph, Ser, 198))",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "83830875b40c4d4d98fbdc72896b9889",
      "variants": [
        {
          "code": "Ser",
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 198
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT, pmod(Ph, Ser, 199))",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "50d3e0e9923f34d9daf851227f55dd1d",
      "variants": [
        {
          "code": "Ser",
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 199
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT, pmod(Ph, Ser, 202))",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "cdcc3b3f116c5db02d04ca383584aef0",
      "variants": [
        {
          "code": "Ser",
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 202
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT, pmod(Ph, Ser, 202), pmod(Ph, Thr, 205))",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "3cbda9484b1c609131d91359822dc2c3",
      "variants": [
        {
          "code": "Ser",
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 202
        },
        {
          "code": "Thr",
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 205
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT, pmod(Ph, Ser, 262))",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "06b0d7203a7f93cbb663eab8b9b593ab",
      "variants": [
        {
          "code": "Ser",
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 262
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT, pmod(Ph, Ser, 396))",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "d20659abb6d812839958a31e9d5d259b",
      "variants": [
        {
          "code": "Ser",
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 396
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT, pmod(Ph, Ser, 404))",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "c0bfbdd9489341f82d82ce560ba52523",
      "variants": [
        {
          "code": "Ser",
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 404
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT, pmod(Ph, Ser, 42))",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "b872125521d4b652fe76648814f5e375",
      "variants": [
        {
          "code": "Ser",
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 42
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT, pmod(Ph, Ser, 422))",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "393be594a81d2f0c5386c424aa4cc22b",
      "variants": [
        {
          "code": "Ser",
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 422
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT, var(\"?\"))",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "82ca363b9b9e9f7f2e880d0674096ecf",
      "variants": [
        {
          "hgvs": "?",
          "kind": "hgvs"
        }
      ]
    },
    {
      "bel": "p(HGNC:PPME1)",
      "concept": {
        "name": "PPME1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "6502fa3f17eeb6dd2b60a50105fa17b9"
    },
    {
      "bel": "p(HGNC:PPP2R2A)",
      "concept": {
        "name": "PPP2R2A",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "e44251a05a824325cdf1dbb55dc62950"
    },
    {
      "bel": "p(HGNC:SET)",
      "concept": {
        "name": "SET",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "294a0ad3a51c1a8636d56b2118d5ea69"
    },
    {
      "bel": "p(HGNC:TPK1)",
      "concept": {
        "name": "TPK1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "f39649b8b2f22f7cb44840a6fb8a6d8e"
    },
    {
      "bel": "path(MESH:\"Alzheimer Disease\")",
      "concept": {
        "name": "Alzheimer Disease",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "2ae8307f5fd59056199369691367cc96"
    },
    {
      "bel": "path(MESH:\"Down Syndrome\")",
      "concept": {
        "name": "Down Syndrome",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "4b9d346d5e19e3224a1157409ce16510"
    },
    {
      "bel": "path(MESH:\"Frontotemporal Dementia\")",
      "concept": {
        "name": "Frontotemporal Dementia",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "876d8dfbadfb211122e2ba889d763c19"
    },
    {
      "bel": "path(MESH:Neoplasms)",
      "concept": {
        "name": "Neoplasms",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "721141fdf3882c4e50f26485962a29e4"
    },
    {
      "bel": "r(HGNC:PPP2CA)",
      "concept": {
        "name": "PPP2CA",
        "namespace": "HGNC"
      },
      "function": "RNA",
      "id": "eeffebfd73289948a93d02833b352ff3"
    },
    {
      "bel": "r(HGNC:PPP2CB)",
      "concept": {
        "name": "PPP2CB",
        "namespace": "HGNC"
      },
      "function": "RNA",
      "id": "f211b2c7564e34c107464e9cecebc0f8"
    }
  ]
}